Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Pfizer38 enrolled

Overview

This study will evaluate whether AG-013736 when combined with cisplatin and gemcitabine shows activity and is safe in patients with squamous type of non-small cell lung cancer

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Carcinoma, Non-Small-Cell Lung (NSCLC)

Interventions

AG-013736DRUG

AG-013736 5 mg tablets orally, twice daily, until disease progression

gemcitabineDRUG

200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m\^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles

cisplatinDRUG

1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m\^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically- or cytologically-confirmed diagnosis of squamous NSCLC Stage IIIB with malignant effusion (fluid cytology demonstrating malignant cells required), Stage IV, or recurrent disease after definitive local therapy * Candidate for primary treatment with cisplatin and gemcitabine * Presence of measurable disease by RECIST * Adequate organ function as defined by the following criteria: ECOG performance status of 0 or 1 Exclusion Criteria: * Prior systemic treatment for Stage IIIB (with malignant effusion) or Stage IV NSCLC. * One or more lung lesions with cavitation, or any lesion invading or abutting a major blood vessel as assessed by CT or MRI. * History of hemoptysis \> ½ tsp (2.5 ml) of blood per day for a day or more within 1 week of study treatment, or Grade 3 or 4 hemoptysis within 4 weeks of study treatment * NCI CTCAE Grade 3 hemorrhage from any cause within 4 weeks of study treatment * Preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. * Untreated brain metastases. * Need for therapeutic anticoagulation, regular use of aspirin (\> 325 mg/day), NSAID or other medications known to inhibit platelet function.

Locations (10)

Pfizer Investigational Site

Torun, Poland

Pfizer Investigational Site

Wodzislaw Sl., Poland

Pfizer Investigational Site

Cluj-Napoca, Cluj, Romania

Pfizer Investigational Site

Bucharest, Romania

Outcomes

Primary Outcomes

Percentage of Participants With Objective Response (OR)

Percentage of participants with objective response based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are those with disappearance of all target lesions. PR are those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions.

Time frame: Baseline until disease progression or discontinuation from the study due to any cause, assessed every 6 weeks during chemotherapy phase and every 8 weeks during single agent phase up to final study visit (Week 78)

Secondary Outcomes

Overall Survival (OS)

Time in months from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame: Baseline until death or assessed every 2 months (up to 28 days after the last dose)

Progression Free Survival (PFS)

Time in months from start of study treatment to the first documentation of objective tumor progression or to death due to any cause. PFS calculated as (Months) = (first event date minus first dose date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame: Baseline, assessed every 2 months (up to 28 days after the last dose)

Duration of Response (DR)

Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.